FERTILITY CAPSULE VI (FSH & LH)

Fertility Capsule VI is a blood-test panel that measures Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). These two hormones are produced by the pituitary gland and work together to regulate reproductive development and function. In females, they help control follicle development, ovulation and the menstrual cycle. In males, they support testosterone production and the development of sperm.

FSH and LH form part of the communication system between the hypothalamus, pituitary gland and ovaries or testes. Measuring both hormones can help doctors assess whether reproductive symptoms may be related to the ovaries or testes, or to insufficient stimulation from the pituitary gland or hypothalamus.

This panel provides useful hormonal information but cannot independently diagnose infertility or confirm that a person is fertile. It does not measure AMH, estradiol, progesterone, prolactin, TSH or testosterone. It also cannot assess egg quality, fallopian-tube patency, uterine structure or semen quality. Results must be interpreted with age, sex, menstrual-cycle timing, symptoms and other investigations.

Benefits of the Test

• Measures two essential pituitary reproductive hormones.
• Supports assessment of ovarian and testicular hormone signalling.
• Helps investigate irregular or absent menstrual periods.
• May support evaluation of suspected ovulatory dysfunction.
• Contributes to the hormonal assessment of female infertility.
• May support evaluation of low sperm count or male infertility.
• Helps investigate early or delayed puberty when clinically indicated.
• May help distinguish primary reproductive-organ dysfunction from pituitary or hypothalamic causes.
• Provides both hormone results from one blood collection.

Why Doctors Recommend This Test

A doctor may recommend FSH and LH testing when a woman has difficulty becoming pregnant, irregular menstrual cycles, absent periods or symptoms suggesting altered ovarian function. The tests may also be requested when premature ovarian insufficiency, menopause, PCOS or pituitary dysfunction is being considered.

FSH stimulates ovarian follicles to grow and supports the development of an egg. LH contributes to final follicle development and triggers ovulation through a mid-cycle surge. Concentrations of both hormones change throughout the menstrual cycle, so the exact collection day is important when interpreting female results.

In males, FSH acts primarily on the sperm-producing structures in the testes, while LH stimulates the Leydig cells to produce testosterone. Abnormal results may help doctors determine whether reduced reproductive function is related to a testicular problem or inadequate stimulation from the pituitary gland.

FSH and LH may also be tested when a patient has symptoms suggesting a pituitary or hypothalamic disorder. The hypothalamus signals the pituitary gland, which releases FSH and LH. Low or inappropriately normal hormone levels in a person with impaired reproductive function may indicate that this signalling pathway requires further evaluation.

In children and adolescents, these tests may be requested when puberty appears to begin unusually early or is significantly delayed. The results must be interpreted according to age, physical development and other hormone tests by a paediatric specialist.

Although FSH and LH are important, they rarely provide a complete fertility assessment alone. Doctors may request AMH, estradiol, progesterone, prolactin, TSH or testosterone depending on the patient's sex, symptoms and reproductive history.

Preparation Before Test

A venous blood sample is collected from a vein in the arm. Fasting is generally not required solely for FSH and LH testing. However, follow the instructions provided by the doctor or Focus Diagnostics, particularly when other fasting tests are ordered at the same time.

Female patients should inform the doctor and laboratory about the first day of their last menstrual period, usual cycle length and whether their cycles are regular. For baseline fertility assessment, FSH and LH are commonly measured during the early follicular phase, often around cycle days 2 to 5. The correct day depends on the clinical question.

Cycle day 1 is generally counted as the first day of full menstrual bleeding rather than light spotting. Women with absent or highly irregular periods should ask their doctor when the sample should be collected rather than selecting a cycle day independently.

Inform the doctor about pregnancy, breastfeeding, menopause, PCOS, ovarian or testicular surgery, pituitary disease, recent illness, cancer treatment and current fertility treatment. These factors may affect hormone concentrations or interpretation.

Provide a complete list of prescribed medicines, non-prescription medicines, vitamins and supplements. Fertility medicines, hormonal contraceptives, estrogen, progesterone, testosterone, anabolic steroids and other hormonal treatments may influence FSH and LH results. Biotin may interfere with some laboratory immunoassays.

Do not stop contraception, fertility medicine or any prescribed treatment unless specifically instructed by the treating doctor. If the result is unexpected or does not match the symptoms, repeat testing or additional hormone investigations may be recommended.

Normal Reporting Time

Fertility Capsule VI is generally reported on the same day or within 24 hours after the laboratory receives an acceptable blood sample. Both hormones are commonly measured using an automated immunoassay analyser.

The actual turnaround time may vary according to collection time, laboratory workload, analyser availability, quality-control procedures and the need to repeat or verify an unexpected result. Patients requiring the report before a fertility appointment or treatment cycle should confirm the expected reporting time with the collection centre.

Who Should Take This Test?

This panel may be suitable for women experiencing difficulty becoming pregnant, irregular menstrual periods, absent periods or suspected ovulatory problems. It may also be recommended for women with symptoms of premature ovarian insufficiency or menopause when testing is clinically appropriate.

Men undergoing infertility assessment may require FSH and LH testing, particularly when a semen analysis shows a low sperm count or when symptoms suggest low testosterone or testicular dysfunction. Total testosterone and other investigations are commonly required for complete interpretation.

People with suspected pituitary or hypothalamic dysfunction may also be advised to undergo FSH and LH testing. Symptoms may include delayed puberty, reduced sexual desire, menstrual changes or reduced reproductive function.

Children or adolescents with unusually early or delayed puberty may require these tests as part of a specialist evaluation. Adult reference intervals must not be used to interpret paediatric results.

This test is not required as a routine fertility guarantee for every person. A healthcare professional should decide whether FSH and LH alone are appropriate or whether a broader fertility profile is needed.

Understanding FSH and LH

Follicle-Stimulating Hormone in females: FSH stimulates the growth of ovarian follicles during the first part of the menstrual cycle. As the ovaries respond, they produce estradiol and other signals that regulate further FSH release. An increased early-cycle FSH result may be associated with reduced ovarian response or ovarian insufficiency.

A normal FSH result does not guarantee normal ovarian reserve or fertility. FSH can vary between menstrual cycles and may be influenced by estradiol. AMH and antral follicle count may be recommended for broader ovarian-reserve assessment.

Luteinizing Hormone in females: LH supports ovarian hormone production and triggers ovulation through a rapid mid-cycle increase called the LH surge. A single blood LH result outside the expected surge cannot reliably prove that ovulation has or has not occurred.

Increased LH may occur around ovulation, after menopause and in some women with PCOS. However, an increased LH level or LH-to-FSH ratio does not diagnose PCOS. Diagnosis requires clinical assessment and other findings.

Follicle-Stimulating Hormone in males: FSH supports the cells involved in sperm production. Increased FSH may be associated with impaired testicular sperm-producing function. Low FSH may indicate insufficient pituitary or hypothalamic stimulation, but semen analysis is required to assess sperm directly.

Luteinizing Hormone in males: LH stimulates the testes to produce testosterone. Low testosterone with increased LH may suggest reduced testicular response, while low testosterone with low or inappropriately normal LH may indicate a pituitary or hypothalamic cause. Testosterone is not included in this panel and may need separate testing.

Detailed Information

The hypothalamus releases gonadotropin-releasing hormone, which stimulates the pituitary gland to produce FSH and LH. These hormones then act on the ovaries or testes. Hormones produced by the reproductive organs send feedback signals to the brain and pituitary gland, helping regulate the system.

Doctors interpret FSH and LH as a pattern. Increased levels may indicate that the pituitary gland is producing more stimulation because the ovaries or testes are responding inadequately. Low levels may indicate insufficient signalling from the hypothalamus or pituitary gland. The interpretation depends on sex, age, menstrual phase and other hormone results.

In females, FSH and LH vary significantly across the cycle. Reference values for the follicular phase, ovulatory phase, luteal phase and postmenopausal period are different. The report should therefore be interpreted using the appropriate cycle phase.

In males, FSH and LH are commonly assessed with total testosterone and semen analysis. An isolated abnormal hormone result cannot establish the precise cause of infertility. Depending on the findings, doctors may recommend prolactin, thyroid tests, genetic studies, ultrasound or specialist examination.

A normal FSH and LH profile does not exclude fertility problems. Female fertility evaluation may additionally require AMH, estradiol, progesterone, pelvic ultrasound, ovulation assessment, tubal-patency testing and examination of the uterus. Male evaluation generally requires semen analysis.

Reference intervals vary between laboratories according to method, population, sex, age and reproductive status. Patients should use the intervals printed on their Focus Diagnostics report rather than comparing the values with another laboratory or an online chart.

An abnormal result does not automatically indicate permanent infertility. Hormonal changes may be temporary, medicine-related or manageable. Fertility medicines or hormonal treatment should not be started or changed solely on the basis of FSH and LH results without professional medical advice.